Aptose Biosciences Inc. (TSE:APS) Expected to Earn Q2 2022 Earnings of ($0.17) Per Share

Aptose Biosciences Inc. (TSE:APS – Get Rating) (NASDAQ:APTO) – Oppenheimer upped their Q2 2022 earnings per share (EPS) estimates for shares of Aptose Biosciences in a report released on Monday, May 9th. Oppenheimer analyst M. Biegler now anticipates that the biotechnology company will post earnings per share of ($0.17) for the quarter, up from their previous forecast of ($0.18). Oppenheimer also issued estimates for Aptose Biosciences’ Q3 2022 earnings at ($0.17) EPS, Q4 2022 earnings at ($0.17) EPS, FY2022 earnings at ($0.66) EPS, FY2023 earnings at ($0.69) EPS and FY2024 earnings at ($0.49) EPS.

Aptose Biosciences (TSE:APS – Get Rating) (NASDAQ:APTO) last posted its quarterly earnings results on Tuesday, March 22nd. The biotechnology company reported C($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.23) by C($0.11).

Several other brokerages have also weighed in on APS. Cantor Fitzgerald reissued an “overweight” rating on shares of Aptose Biosciences in a research report on Friday, April 1st. HC Wainwright increased their price objective on shares of Aptose Biosciences to C$12.00 and gave the company a “buy” rating in a research report on Wednesday, March 23rd. Finally, Jonestrading reissued a “buy” rating and issued a C$8.00 price objective on shares of Aptose Biosciences in a research report on Wednesday, March 23rd.

TSE APS opened at C$1.24 on Thursday. The firm has a market capitalization of C$114.36 million and a P/E ratio of -1.31. The firm’s fifty day moving average price is C$1.53 and its two-hundred day moving average price is C$1.91. Aptose Biosciences has a 1 year low of C$1.21 and a 1 year high of C$6.98. The company has a current ratio of 10.00, a quick ratio of 9.68 and a debt-to-equity ratio of 0.77.

Aptose Biosciences Company Profile (Get Rating)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Recommended Stories